Daniel de Boer, ProQR CEO (via YouTube)
In latest antisense failure, ProQR's rare eye disease treatment falls flat
It’s been a bad 12 months for antisense technology.
ProQR, an RNA-focused startup, announced Friday that its lead candidate for one form of a rare …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
